These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29715194)

  • 21. Surgical and anesthetic considerations in histrelin capsule implantation for the treatment of precocious puberty.
    Davis JS; Alkhoury F; Burnweit C
    J Pediatr Surg; 2014 May; 49(5):807-10. PubMed ID: 24851775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experience with the Histrelin Implant in Pediatric Patients.
    Eugster EA
    Endocr Dev; 2016; 30():54-9. PubMed ID: 26683629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical resource use and costs related to central precocious puberty: a retrospective cohort study.
    Chen SY; Fuldeore M; Boulanger L; Fraser KA; Chwalisz K; Marx SE
    Endocr Pract; 2012; 18(4):519-28. PubMed ID: 22440983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraoperative sonographic localization of a fractured Supprelin implant in a pediatric patient: a case report.
    Monroe BJ; Fallon SC; Brandt ML
    J Pediatr Endocrinol Metab; 2012; 25(1-2):167-9. PubMed ID: 22570970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parent reports of adolescents and young adults perceived to show signs of a rapid onset of gender dysphoria.
    Littman L
    PLoS One; 2018; 13(8):e0202330. PubMed ID: 30114286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment and outcomes of precocious puberty: an update.
    Fuqua JS
    J Clin Endocrinol Metab; 2013 Jun; 98(6):2198-207. PubMed ID: 23515450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transgender Children: Conundrums and Controversies--A Introduction to the Section.
    Lament C
    Psychoanal Study Child; 2014; 68():13-27. PubMed ID: 26173324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty.
    Barradell LB; McTavish D
    Drugs; 1993 Apr; 45(4):570-88. PubMed ID: 7684676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pubertal Suppression for Transgender Youth and Risk of Suicidal Ideation.
    Turban JL; King D; Carswell JM; Keuroghlian AS
    Pediatrics; 2020 Feb; 145(2):. PubMed ID: 31974216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Puberty suppression in transgender children and adolescents.
    Mahfouda S; Moore JK; Siafarikas A; Zepf FD; Lin A
    Lancet Diabetes Endocrinol; 2017 Oct; 5(10):816-826. PubMed ID: 28546095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of Puberty Suppression with Gonadotropin-Releasing Hormone Agonists in Transgender Youth.
    Mejia-Otero JD; White P; Lopez X
    Transgend Health; 2021; 6(1):31-35. PubMed ID: 33614957
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of gonadotropin-releasing hormone analogue on final adult height among Jordanian children with precocious puberty.
    Swaiss HH; Khawaja NM; Farahid OH; Batieha AM; Ajlouni KM
    Saudi Med J; 2017 Nov; 38(11):1101-1107. PubMed ID: 29114697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the Care of Transgender Children and Adolescents.
    Shumer DE; Nokoff NJ; Spack NP
    Adv Pediatr; 2016 Aug; 63(1):79-102. PubMed ID: 27426896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Largest ever study of transgender teenagers set to kick off.
    Reardon S
    Nature; 2016 Mar; 531(7596):560. PubMed ID: 27029280
    [No Abstract]   [Full Text] [Related]  

  • 36. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy.
    Pescovitz OH; Comite F; Hench K; Barnes K; McNemar A; Foster C; Kenigsberg D; Loriaux DL; Cutler GB
    J Pediatr; 1986 Jan; 108(1):47-54. PubMed ID: 3080571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mental Health Concerns and Insurance Denials Among Transgender Adolescents.
    Nahata L; Quinn GP; Caltabellotta NM; Tishelman AC
    LGBT Health; 2017 Jun; 4(3):188-193. PubMed ID: 28402749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mental health of transgender youth in care at an adolescent urban community health center: a matched retrospective cohort study.
    Reisner SL; Vetters R; Leclerc M; Zaslow S; Wolfrum S; Shumer D; Mimiaga MJ
    J Adolesc Health; 2015 Mar; 56(3):274-9. PubMed ID: 25577670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists.
    Miller BS; Shukla AR
    Clin Ther; 2010 Sep; 32(10):1749-51. PubMed ID: 21194598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood Pressure Dynamics After Pubertal Suppression with Gonadotropin-Releasing Hormone Analogs Followed by Testosterone Treatment in Transgender Male Adolescents: A Pilot Study.
    Perl L; Segev-Becker A; Israeli G; Elkon-Tamir E; Oren A
    LGBT Health; 2020; 7(6):340-344. PubMed ID: 32735503
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.